Introducing the GEN II Cell Free DNA Production Platform
Elegen’s GEN II Platform incorporates the world’s first directed-split-pool microfluidic synthesizer with Elegen’s patented cell-free cloning technology, a unique combination of AI and robotics that fully automates the production of long, clonal quality, high complexity, double-stranded DNA with unprecedented speed, low costs, and efficiency.
By replacing bulky, expensive synthesizers and eliminating bacteria from cloning, Elegen is able to eliminate the high labor cost, large capital expenditures, and reduce the footprint of high-volume DNA production by more than 10-fold. The compact scale unlocks unprecedented manufacturing agility for Elegen’s differentiated products, including linear DNA up to 7 kb with high-complexity, 19 kb plasmids with up to 15 kb inserts, and most recently, linear DNA with up to 130 base poly(A) tails, immediately ready for in vitro transcription.
AI Driven
Powered by a proprietary LLM that converts customer sequences into production protocols encompassing oligo design, reagent procurement, robotic operation, and production scheduling – all while learning and optimizing in real time.
Capital-efficient
Capable of generating >10X more genes per square foot in comparison to the cell-based factories required by market-leading gene synthesis suppliers.
Low-cost operation
Supported by just two engineers, the entire process — from synthesis to amplification — is miniaturized, using a fraction of the chemicals used in cell-based approaches, significantly reducing the carbon emissions associated with every order.
